Piscataqua Savings Bank increased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 622.1% in Q1, according to its latest SEC filing. The fund held 29,584 shares of the company after purchasing an additional 25,487 shares during the period. Johnson & Johnson owns 3.7% of the holdings of Piscataqua Savings Bank, making it its 6th largest position. Piscataqua Savings Bank’s holdings in Johnson & Johnson were worth $5,243,000 at the end of the last quarter.
Other large investors have also recently changed their holdings in the company. Family CFO Inc acquired a new stake in Johnson & Johnson in Q4 worth approximately $26,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson in Q4 valued at approximately $34,000. Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company valued at $41,000 after purchasing 67 additional shares in the last quarter. Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company valued at $45,000 after buying 61 additional shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson in Q4 valued at approximately $49,000. Institutional investors and hedge funds own 68.78% of the company’s shares.
In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson in a trade that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. As a result of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson in a trade that took place on Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The disclosure of this sale can be found here. Insiders have sold 78,161 shares of the company worth $13,895,302 in the past three months. 0.35% of the shares are currently held by insiders.
Shares of JNJ opened at $179.52 on Friday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company’s 50-day moving average is $177.37 and its 200-day moving average is $173.74. The stock has a market capitalization of $472.39 billion, a PE ratio of 24.19, a P/E/G ratio of 3.61 and a beta of 0.66. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt ratio of 0.39.
Johnson & Johnson (NYSE:JNJ – Get Rating) last reported results on Tuesday, April 19. The company reported EPS of $2.67 for the quarter, beating the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company posted revenue of $23.43 billion for the quarter, versus $23.62 billion expected by analysts. During the same period last year, the company earned earnings per share of $2.59. The company’s revenue for the quarter increased 5.0% year over year. Equity research analysts expect Johnson & Johnson to post earnings per share of 10.23 for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7. Investors of record on Tuesday, May 24 received a dividend of $1.13. This represents a dividend of $4.52 on an annualized basis and a yield of 2.52%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date was Monday, May 23. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
Several research analysts have weighed in on the stock. Sanford C. Bernstein cut Johnson & Johnson shares from an “outperform” rating to a “market performer” rating and raised its price target for the company from $180.00 to $183.00 in a report from Wednesday, March 16. Goldman Sachs Group raised its price target on Johnson & Johnson shares from $163.00 to $181.00 and gave the company a “neutral” rating in a Tuesday, April 12 report. Daiwa Capital Markets assumed coverage for Johnson & Johnson shares in a Wednesday, June 22 report. They issued an “outperformance” rating on the stock. Morgan Stanley lowered its price target on Johnson & Johnson shares from $175.00 to $173.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 report. Finally, StockNews.com upgraded Johnson & Johnson shares from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 report. Four investment analysts gave the stock a hold rating, six gave the company a buy rating and one gave the company’s stock a strong buy rating. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $190.50.
Johnson & Johnson Company Profile (Get an evaluation)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.